(Total Views: 129)
Posted On: 10/22/2025 2:52:59 PM
Post# of 103181
$BCTX receives its 4th consecutive positive DSMB recommendation for its Phase 3 study of Bria-IMT™ in metastatic breast cancer, with no safety concerns and the trial continuing without modification, showing confidence in Bria-IMT’s safety profile.
https://globenewswire.com/news-release/2025/1...ancer.html
#BCTX #Biotech #CancerResearch #BreastCancer #Immunotherapy #MedicalInnovation #HealthTech #Oncology #BioInvesting #Pharma
https://globenewswire.com/news-release/2025/1...ancer.html
#BCTX #Biotech #CancerResearch #BreastCancer #Immunotherapy #MedicalInnovation #HealthTech #Oncology #BioInvesting #Pharma